Amgen Inc.

Julie Anne Heath

Zhihua Ma

David John Kopecky

Xiaoqi Chen

Zice Fu

Xiaodong Wang

Jeffrey Thomas Mihalic

Paul John Dransfield

Vatee Pattaropong

Richard V Connors

Steven H Olson

Jonathan B Houze

Su-Jen Lai

Julio Cesar Medina

Nobuko Nishimura

Jeffrey Deignan

Ning Chen

Mikkel V Debenedetto

Gayathri Swaminath

Lawrence R McGee

Frank Kayser

Xiaohui Du

Matthew R Kaller

Alan C Cheng

Daniel B Horne

Wen-Chen Yeh

Yinhong Chen

Aarif Yusuf Khakoo

Kevin Chao Yang

Ted Charles Judd

Simon J Hedley

Robert P Farrell

James S Harvey

Daqing Sun

Xuelei Yan

Michael G Johnson

Yosup Rew

Felix Gonzalez Lopez De Turiso

Brian M Fox

Michael D Bartberger

John Eksterowicz

Jason A Duquette

Hilary Plake Beck

Ana Zurisadai Gonzalez Buenrostro

Darin J Gustin

Zhihong Li

Joel McIntosh

Jiasheng Fu

Yihong Li

Philip M Roveto

Malgorzata Wanska

Jiang Zhu

Steven Howard Olson

Dustin Mcminn

Michael Johnson

Joel Mcintosh

Richard Victor Connors

Brian Matthew Fox

Lawrence Mcgee

Sujen Lai

Philip Marley Roveto

Xianyun Jiao

Darin James Gustin

Dustin L McMinn

Ming Yu

Jiwen Liu

Jonathan Dante Low

Brian Stuart Lucas

Yingcai Wang

Lars V Heumann

XianYun Jiao

Michael W Gribble, Jr

Xin Huang

Benjamin Fisher

SuJen Lai

Michael William Gribble

Matthew Irvine Brown

Kevin Yang

Charles Kreiman

Michael J Schmitt

Philip Dean Ramsden

Christine Weathers

Lawrence R Mcgee

Jr Gribble

Jeffrey T Mihalic

Julio C Medina

Jonathan Houze

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein. 

Cycloalkyl substituted triazole compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein. 

Triazole phenyl compounds as agonists of the APJ receptor

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Bromotriazole intermediates are useful in the synthesis of agonists of the APH receptor. Such compounds include those selected from 

Bromotriazole intermediates

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers have the following structure and are useful compounds in preparing small molecule agonists of the APJ Receptor: where the definitions of the variables are provided herein.

Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor

Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.

Methods of treating heart failure

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Methods for preparing triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.

Growing community of inventors

Chico, CA, United States of America

Julie Anne Heath